Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

5IBF

Crystal structure Mycobacterium tuberculosis CYP121 in complex with inhibitor fragment 19a

Summary for 5IBF
Entry DOI10.2210/pdb5ibf/pdb
DescriptorMycocyclosin synthase, SULFATE ION, PROTOPORPHYRIN IX CONTAINING FE, ... (5 entities in total)
Functional Keywordsmycobacterium tuberculosis, cyp121, fragment based inhibitor screening, oxidoreductase
Biological sourceMycobacterium tuberculosis
Total number of polymer chains1
Total formula weight44519.01
Authors
Levy, C. (deposition date: 2016-02-22, release date: 2016-04-06, Last modification date: 2024-05-01)
Primary citationKavanagh, M.E.,Coyne, A.G.,McLean, K.J.,James, G.G.,Levy, C.W.,Marino, L.B.,de Carvalho, L.P.,Chan, D.S.,Hudson, S.A.,Surade, S.,Leys, D.,Munro, A.W.,Abell, C.
Fragment-Based Approaches to the Development of Mycobacterium tuberculosis CYP121 Inhibitors.
J.Med.Chem., 59:3272-3302, 2016
Cited by
PubMed Abstract: The essential enzyme CYP121 is a target for drug development against antibiotic resistant strains of Mycobacterium tuberculosis. A triazol-1-yl phenol fragment 1 was identified to bind to CYP121 using a cascade of biophysical assays. Synthetic merging and optimization of 1 produced a 100-fold improvement in binding affinity, yielding lead compound 2 (KD = 15 μM). Deconstruction of 2 into its component retrofragments allowed the group efficiency of structural motifs to be assessed, the identification of more LE scaffolds for optimization and highlighted binding affinity hotspots. Structure-guided addition of a metal-binding pharmacophore onto LE retrofragment scaffolds produced low nanomolar (KD = 15 nM) CYP121 ligands. Elaboration of these compounds to target binding hotspots in the distal active site afforded compounds with excellent selectivity against human drug-metabolizing P450s. Analysis of the factors governing ligand potency and selectivity using X-ray crystallography, UV-vis spectroscopy, and native mass spectrometry provides insight for subsequent drug development.
PubMed: 27002486
DOI: 10.1021/acs.jmedchem.6b00007
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.7 Å)
Structure validation

227344

건을2024-11-13부터공개중

PDB statisticsPDBj update infoContact PDBjnumon